Taiwan headquartered specialty pharma Sunny Pharmtech (Sunny) announced today that it has successfully developed the generic version of AMICAR®, a fibrinolysis inhibitor, of Clover Pharmaceutical for the US market. Indications for AMICAR® include the inhibition of plasminogen activators which could cause hypoprothrombinemia. It can also be used in the treatment of abnormal bleeding syndromes from surgeries and other hematological diseases. Sunny also said that it has chosen Lotus Pharmaceutical (Lotus) to be its CMO partner in the commercialization of AMA.
Sunny is a vertically integrated specialty pharma that specializes in the development of both API and formulation. Commenting on the partnership, Chairman and CEO of Sunny, Dr. Yon-Lian Wu said,
Lotus Chairman Andrew Lin was excited about working together with such an experienced, dedicated team. He said,